Table 1.
FPR1 involvement in cardiovascular diseases (CVDs).
| CVDs | Expression and/or Stimulation | Role |
|---|---|---|
| Ischemia reperfusion injury (IRI) | FPR1 deficiency m | Protective effects by reducing the risk of heart injury induced by IRI [65] |
| FPR1 silencing r | Protective effects mediated by depression of inflammation, cardiomyocyte apoptosis and ventricular remodeling in rats with I/R injury through the suppression of the MAPK signaling pathway activation [66] | |
| FPR1 antagonist CSH m | Protective effects by reducing hepatocyte necrosis/apoptosis, and diminishing inflammatory cytokine, chemokine, and oxidative stress levels as well as accumulation of neutrophils in the necrotic area [67] | |
| FPR1 stimulation with ANXA1 m and r | Cardioprotective role by preserving inotropic responsiveness at the level of ventricular muscle and contractile function of cardiac muscle in vitro [70,71,72,73] | |
| FPR1 blockade m | Beneficial effects mediated by abrogation of reperfusion-induced exacerbation of infarct size [78] | |
| Blood pressure (BP) levels | FPR1 C32T (rs5030878) single nuclear polymorphism (SNP) h | Negative prognostic factor and detrimental effects associated with increased C-reactive protein (CRP) levels linearly related with BP [83,84,85] |
| Abdominal aortic aneurysm (AAA) | FPR1 involvement m | Detrimental effects since FPR1 results involved in neutrophil recruitment and aggravated AAA development [91] |
| Acute myocardial infarction (AMI) | FPR1 as a differentially expressed gene (DEG) h | Role has to be determined even if FPR1 results a DEG in human AMI blood tissue, compared with normal blood tissue using microarray data [75] |
| Potential beneficial role for AMI prevention [76] | ||
| Platelet-mediated complications | FPR1 inhibition or gene deletion m and h | Detrimental effects by impairing agonist-induced platelet activation in Fpr1-deficient mice or in pharmacologically FPR1 inhibited human platelets [94] |
| Endothelial cell function and HUVECs | FPR1 stimulation with NfMLF hc | Beneficial effects by promoting proliferation and capillary network formation |
| Angiogenesis | FPR1 stimulation with ANXA1 hc | Beneficial effects by inducing angiogenesis and/or production of angiogenic factors [56,57,58] |
Table legend: m = mouse; r = rat; h = human; hc = human cell.